Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE) and Idexx Laboratories (IDXX). According to TipRanks.com, Tewari is a 5-star analyst with an average ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform ...

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...

It’s rare to get such a massive high-yielder that’s also positioning itself for long-term growth. Of course, shares of Pfizer ...

Pfizer, Inc. (PFE) reported strong earnings and earnings guidance on Feb. 3. Large, unusual call option activity today, as seen in a Barchart report, shows that investors are bullish. PFE is at $27.72 ...

Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic ...

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...